The methylation level of the CpG site adjacent to the MZF1 binding site was 13.8% in endometrial cancer tissues and 4.0% in normal tissues, indicating that hypermethylation may attenuate the repressive regulation of MZF1 by preventing its binding to the PAX2 promoter and further up-regulate PAX2 transcription. This evidence concerns the gene PAX2 and endometrial cancer.